surmount-1 tirzepatide Lilly Shows Superiority in SURMOUNT-3 and 4 Tirzepatide once weekly for the

In SURMOUNT-1: Tirzepatide 5 mg: Mean 15.0% body weight loss at 72 weeks Tirzepatide 10 mg: Mean 19.5% body weight loss at 72 weeks Tirzepatide 15 mg: Mean 20.9% body weight loss at 72 weeks Placebo: 3.1% body weight loss at 72 weeks On a per-week basis, most patients lose 12 pounds weekly during titration and the first 6 months, with the rate gradually slowing as the body approaches a new metabolic equilibrium

Glucagon-like peptide-1 (GLP-1)-based therapies improve all these variables but whether the dual GLP-1 / glucose-dependent insulinotropic polypeptide (GIP) agonist tirzepatide is superior to semaglutide in attaining therapeutic targets remains unclear

Furihata K, Mimura H, Urva S, Oura T, Ohwaki K, Imaoka T

doi:10.1186/s10194-022-01402-2